Fig. 1 · Structure

Documents & Downloads

Azelnidipine

Cat. No. A11219 CAS 123524-52-7

calcium channel blocker

Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. that attenuates liver fibrosis and may increase antioxidant defence.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Calcium channel

Cellular Effect

Cell Line Activity Value Description Reference
LLC-MK2 IC50 2.9 μM Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay [PMID: 20934347]
LLC-MK2 IC50 33.48 μM Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay [PMID: 20934347]

Azelnidipine Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Azelnidipine from 3 published references. In vitro models include His tagged human SIRPα; KYSE150.

Azelnidipine In Vitro Studies

Incubation of His tagged human SIRPα with serially diluted Azelnidipine yielded a reported KD of 5.37 μM. In KYSE150 cells treated with Azelnidipine, the half-maximal inhibitory concentration was 10.972 μM at 24 h and 9.411 μM at 48 h. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Azelnidipine binding assessment with human SIRPα

Cell-based study · His tagged human SIRPα [1]

His tagged human SIRPα was incubated with Azelnidipine serially diluted from 200 μM for 5 min at room temperature. The reported KD was 5.37 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
KD valuesKD 5.37 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
2-fold serially diluted from 200 μM
Exposure duration
5 min at room temperature
Method
incubated with the diluted azelnidipine
Reported limits
Not stated in the sentences used: vehicle, control.
Methods and source locations

Compound reported in the paper: Azelnidipine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.6. Microscale Thermophoresis (MST) (S27, S28, S29, S30, S31); 3. Results > 3.4. The Binding Activity and Model of Azelnidipine to SIRPα and PVR (S94)

KD values: KD values — 2. Materials and Methods > 2.6. Microscale Thermophoresis (MST) (S31); 3. Results > 3.4. The Binding Activity and Model of Azelnidipine to SIRPα and PVR (S94)

Azelnidipine inhibitory concentration assessment in KYSE150

Cell-based study · KYSE150 [2]

KYSE150 cells were treated with various concentrations of Azelnidipine. The half-maximal inhibitory concentration was 10.972 μM at 24 h and 9.411 μM at 48 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
half-maximal inhibitory concentration (IC50)IC50 10.972 μM at 24 h and 9.411 μM at 48 h[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 5, 10, 15, and 20 μM
Exposure duration
24 and 48 h
Method
treated with various concentrations of azelnidipine
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Azelnidipine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Azelnidipine inhibits ESCC cell proliferation in vitro (S5); Materials and methods > Cytotoxicity assay and proliferation assay (S85, S88)

half-maximal inhibitory concentration (IC50): half-maximal inhibitory concentration (IC50); comparator: 0 μM — Results > Azelnidipine inhibits ESCC cell proliferation in vitro (S5)

Azelnidipine In Vivo Studies

In SCID/CB17 mice bearing EG20 patient-derived xenografts, daily oral gavage of Azelnidipine at 2 mg/kg for 42 days significantly reduced tumor weights compared with vehicle, with a reported reduction of 66.45%. In male Wistar rats receiving NA, oral Azelnidipine was studied against an NA group without vasodilator treatment. The rat study reported that treatments with azelnidipine and hydralazine lowered SBP and DBP, while these effects were partially insignificant. [2,3]

Azelnidipine treatment in patient-derived xenografts

Animal study · EG20; SCID/CB17 mice; patient-derived xenograft (PDX) [2]

SCID/CB17 mice bearing EG20 patient-derived xenografts received Azelnidipine at 2 mg/kg by daily oral gavage for 42 days. Tumor weights were significantly reduced compared with the vehicle group, with a reported reduction of 66.45%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor weightstumor weights 66.45%[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
42 days; daily
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Azelnidipine 2 mg/kgvehicle groupThe tumor weights of the azelnidipine-treated group were significantly reduced compared with the vehicle group (EG20: 66.45% at 2 mg/kg group[2]
Azelnidipine 2 mg/kg
Model: EG20; SCID/CB17 mice; patient-derived xenograft (PDX)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Azelnidipine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Azelnidipine inhibits PDX tumor growth in vivo (S61, S62, S64); Materials and methods > PDX model (S133, S134)

tumor weights: tumor weights; comparator: vehicle group — Results > Azelnidipine inhibits PDX tumor growth in vivo (S64)

Azelnidipine 2 mg/kg · Results > Azelnidipine inhibits PDX tumor growth in vivo (S62, S64)

Azelnidipine treatment in NA-treated Wistar rats

Animal study · 8-week-old male Wistar rats; NA plus azelnidipine, 8 [3]

Male Wistar rats receiving NA were given Azelnidipine orally over 14 days, with an NA group without vasodilator treatment as the comparator. The study reported that treatments with azelnidipine and hydralazine lowered SBP and DBP, while these effects were partially insignificant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
averages of SBP and DBPReported result Treatments with azelnidipine and hydralazine lowered SBP and DBP, while these effects were partially insignificant.[3]

Conditions shared by the study groups

Route
oral administration
Treatment course
over 14 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Azelnidipine 9.7 ± 0.3 mg/dayNA group without vasodilator treatmentTreatments with azelnidipine and hydralazine lowered SBP and DBP, while these effects were partially insignificant.[3]
Azelnidipine 9.7 ± 0.3 mg/day
Model: 8-week-old male Wistar rats; NA plus azelnidipine, 8
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Azelnidipine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animals and chemicals (S1); Methods > BP monitoring and experiment protocol (S9, S10, S13, S14); Results (S26, S28, S33); Fig. 1 legend (S48, S49)

averages of SBP and DBP: averages of SBP and DBP; comparator: NA group without vasodilator treatment — Results (S26, S28)

Azelnidipine 9.7 ± 0.3 mg/day · Methods > BP monitoring and experiment protocol (S9); Results (S28, S33)

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 123524-52-7
Applications calcium channel blocker
Formula C33H34N4O6
Molecular Weight 582.7
SMILES
CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 115 mg/mL (197.37 mM)
Water Insoluble
Ethanol 7 mg/mL (12.01 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+30% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Azelnidipine Research References

  1. [1] Zhou X, Jiao L, Qian Y, et al. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy. Biomolecules (2021). PMID: 34068552 DOI: 10.3390/biom11050706 Source material
  2. [2] Zhao L, Zhang Y, Li A, et al. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2. Mol Ther Oncolytics (2022). PMID: 36284716 DOI: 10.1016/j.omto.2022.09.007 Source material
  3. [3] Jiang D, Matsuzaki M, Ida T, et al. Effects of vasodilators on beat-to-beat and every fifteen minutes blood pressure variability induced by noradrenaline infusion in rats. Hypertens Res (2024). PMID: 38337004 DOI: 10.1038/s41440-024-01595-w Source material

Added to your cart

View Cart Checkout
Loading...